4.8 Letter

Procalcitonin in intensive care units: the PRORATA trial

期刊

LANCET
卷 375, 期 9726, 页码 1605-1605

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)60695-2

关键词

-

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pediatrics

Neurodevelopmental outcomes of preterm infants after randomisation to initial resuscitation with lower (FiO2 ≤0.3) or higher (FiO2 ≥0.6) initial oxygen levels. An individual patient meta-analysis

Ju Lee Oei, Vishal Kapadia, Yacov Rabi, Ola Didrik Saugstad, Denise Rook, Marijn J. Vermeulen, Nuria Boronat, Valerie Thamrin, William Tarnow-Mordi, John Smyth, Ian M. Wright, Kei Lui, Johannes B. van Goudoever, Val Gebski, Maximo Vento

Summary: In this study, resuscitation with lower or higher initial FiO2 was not associated with the risk of death or disability at 2 years in infants under 32 weeks gestation. However, the wide confidence intervals indicate that conclusive evidence is lacking, and larger randomized studies are urgently needed to further investigate the potential benefits or harms of different initial FiO2 levels on infant outcomes.

ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION (2022)

Article Multidisciplinary Sciences

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

Fiona Chionh, Val Gebski, Sheren J. Al-Obaidi, Jennifer K. Mooi, Maressa A. Bruhn, Chee K. Lee, Anderly C. Chueh, David S. Williams, Andrew J. Weickhardt, Kate Wilson, Andrew M. Scott, John Simes, Jennifer E. Hardingham, Timothy J. Price, John M. Mariadason, Niall C. Tebbutt

Summary: The study found that SNPs in the VEGF-A and VEGFR2 genes may have predictive value for treatment outcomes and the development of hypertension in patients with colorectal cancer.

SCIENTIFIC REPORTS (2022)

Article Oncology

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer

K. E. Francis, S. Kim, M. Friedlander, V Gebski, I Ray-Coquard, A. Clamp, R. T. Penson, A. Oza, T. Perri, T. Huzarski, C. Martin-Lorente, S. C. Cecere, N. Colombo, B. Ataseven, K. Fujiwara, G. Sonke, I Vergote, E. Pujade-Lauraine, J-W Kim, C. K. Lee

Summary: Using data from the SOLO2 trial, this study evaluated the impact of dose alterations on survival outcomes of olaparib treatment and identified baseline characteristics associated with dose alteration.

ANNALS OF ONCOLOGY (2022)

Meeting Abstract Oncology

Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER plus ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial

N. Murray, P. Francis, N. Zdenkowski, N. Wilcken, F. Boyle, V. Gebski, S. M. Tiley, L. Gilham, S-J. Dawson, S. Loi, A. D. Redfern, J. Lombard, A. Spillane, C. Shadbolt, H. Badger

ANNALS OF ONCOLOGY (2022)

Article Oncology

A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol

Sina Vatandoust, David Wattchow, Luigi Sposato, Michael Z. Michael, John Leung, Kirsten Gormly, Gang Chen, Erin L. Symonds, Jeanne Tie, Lito Electra Papanicolas, Susan Woods, Val Gebski, Kelly Mead, Aleksandra Kuruni, Christos S. Karapetis

Summary: This study aims to investigate the safety of the watch and wait approach for rectal cancer patients, as well as explore the use of predictive biomarkers and patient reported outcome measures. It also seeks to evaluate a defined monitoring schedule for patients managed with the watch and wait approach, and assess the cost effectiveness of this approach.

BMC CANCER (2022)

Article Oncology

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

R. Mercieca-Bebber, E. H. Barnes, K. Wilson, Z. Samoon, E. Walpole, T. Mai, S. Ackland, M. Burge, G. Dickie, D. Watson, J. Leung, T. Wang, R. Bohmer, D. Cameron, J. Simes, V Gebski, M. Smithers, J. Thomas, J. Zalcberg, A. P. Barbour

Summary: This study evaluates the patient-reported outcomes (PROs) of different treatment groups in patients with resectable oesophageal adenocarcinoma. The results show that similar proportions of patients in different treatment groups had PRO scores within 10 points of their baseline scores, indicating similar symptom experiences. However, non-responders who received docetaxel with or without radiotherapy experienced additional burden compared to responders, reflecting the longer duration of neoadjuvant treatment and additional toxicity.

BMC CANCER (2022)

Article Oncology

Toward Incorporating Health-Related Quality of Life as Coprimary End Points in Clinical Trials: Time to Achieve Clinical Important Differences and QoL Profiles

Val Gebski, Andreas Obermair, Monika Janda

Summary: In addition to morbidity and mortality, quality of life (QoL) is an important outcome of cancer treatments. This study proposes a method to incorporate QoL as coprimary endpoints in clinical trial designs and provides metrics to evaluate QoL outcomes. The analysis of a clinical trial comparing laparoscopic and abdominal surgery for endometrial cancer showed that laparoscopic surgery had a shorter time to achieving a clinically important difference in physical and functional well-being QoL domains compared to abdominal surgery. The methods introduced in this study can help healthcare professionals counsel patients about both QoL and clinical outcomes simultaneously.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Oncology

Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis

Sandy Simon, Katherine E. Francis, Janene E. Dalrymple, Val Gebski, Sarah J. Lord, Michael Friedlander, Chee Khoon Lee

Summary: Non-drug-related adverse events are common in ovarian cancer patients in maintenance therapy RCTs. Potential explanations include the nocebo effect, residual toxicities from previous treatment, or underlying disease.

EUROPEAN JOURNAL OF CANCER (2022)

Article Oncology

Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study

Robert P. Carroll, Michael Boyer, Val Gebski, Bronwyn Hockley, Julie K. Johnston, Svjetlana Kireta, Hsiang Tan, Anne Taylor, Kate Wyburn, John RZalcberg

Summary: Maintaining baseline immunosuppression before treatment with an immune checkpoint inhibitor in kidney transplant recipients might not affect expected efficacy and might reduce the risk of allograft rejection mediated by immune checkpoint inhibitors.

LANCET ONCOLOGY (2022)

Article Oncology

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

Magnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Doebeln, Fernanda Villegas, Giovanna Gagliardi, Mats Hellstroem, Qiao-Li Wang, Hemming Johansson, Val Gebski, Jakob Hedberg, Fredrik Klevebro, Sheraz Markar, Elizabeth Smyth, Pernilla Lagergren, Ghazwan Al-Haidari, Lars Cato Rekstad, Eirik Kjus Aahlin, Bengt Wallner, David Edholm, Jan Johansson, Eva Szabo, John V. Reynolds, C. S. Pramesh, Naveen Mummudi, Amit Joshi, Lorenzo Ferri, Rebecca K. S. Wong, Chris O'Callaghan, Jelena Lukovic, Kelvin K. W. Chan, Trevor Leong, Andrew Barbour, Mark Smithers, Yin Li, Xiaozheng Kang, Feng-Ming Kong, Yin-Kai Chao, Tom Crosby, Christiane Bruns, Hanneke van Laarhoven, Mark van Berge Henegouwen, Richard van Hillegersberg, Riccardo Rosati, Guillaume Piessen, Giovanni de Manzoni, Florian Lordick

Summary: This study aims to compare the overall survival and quality of life between neoadjuvant chemoradiotherapy (nCRT) followed by surgery and definitive chemoradiotherapy (dCRT) followed by surveillance and salvage esophagectomy, in patients with operable, locally advanced esophageal squamous cell carcinoma (ESCC).

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

Katrin M. Sjoquist, Andrew Martin, Nick Pavlakis, David Goldstein, Eric Tsobanis, Daniel Moses, Richard Maher, Wendy Hague, Val Gebski, Martin R. Stockler, R. John Simes

Summary: This study assessed the value of central review in evaluating PFS times in phase 2 clinical trials and found that it supported the reliability of trial results and conclusions.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

Groin Surveillance by Serial Ultrasonography Rather Than Sentinel Node Biopsy or Inguinofemoral Lymphadenectomy for Patients with Vulvar Cancer: A Pilot Study

Neville F. Hacker, Ellen L. Barlow, Glenn McNally, Stephen Morrell, Val Gebski, Andreas Obermair

Summary: Vulvar cancer is a rare disease that often leads to body image issues due to its treatment. Chronic lower limb lymphedema is a common problem after the removal of groin lymph nodes. The status of these nodes is crucial for prognosis, and most patients require groin dissection. A pilot study on 32 patients showed promising results for serial ultrasonography as a potential alternative to groin dissection in selected patients. The study achieved a high sensitivity and specificity in detecting positive nodes, supporting the need for further research on this approach.

CANCERS (2023)

Meeting Abstract Oncology

A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer

Chee Lee, Val Gebski, Katherine Francis, Julien Grenier, Julia Welz, Anna Maria Mosconi, Maria Jesus Rubio-Perez, Christoph Grimm, Takashi Matsumoto, Ignace Vergote, Nicoletta Colombo, Mansoor Raza Mirza, Philippe Follana, Nikolaus de Gregorio, Claudio Zamagni, Yolanda Garcia-Garcia, Jerome Meunier, Eric Pujade-Lauraine, Michael Friedlander, Isabelle Ray-Coquard

GYNECOLOGIC ONCOLOGY (2022)

Meeting Abstract Oncology

Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis

Pedro Ramirez, Michael Frumovitz, Rene Pareja, David Isla, Kristy Robledo, Rebecca Asher, Val Gebski, Vanessa Behan, Aldo Lopez, Reitan Ribeiro, Xiaojian Yan, Robert Coleman, Andreas Obermair

GYNECOLOGIC ONCOLOGY (2022)

Meeting Abstract Oncology

Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).

Linda R. Mileshkin, Kathleen N. Moore, Elizabeth H. Barnes, Yeh Chen Lee, Val Gebski, Kailash Narayan, Nathan Bradshaw, Katrina Diamante, Anthony W. Fyles, William Small, David K. Gaffney, Pearly Khaw, Susan Brooks, J. Spencer Thompson, Warner King Huh, Matthew Carlson, Katina Robison, Danny Rischin, Martin R. Stockler, Bradley J. Monk

JOURNAL OF CLINICAL ONCOLOGY (2022)

暂无数据